These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34253634)

  • 1. Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series.
    Nicholas RS; Rhone EE; Mariottini A; Silber E; Malik O; Singh-Curry V; Turner B; Scalfari A; Ciccarelli O; Sormani MP; Olavarria E; Mehra V; Gabriel I; Kazmi MA; Muraro P;
    Neurology; 2021 Aug; 97(9):e890-e901. PubMed ID: 34253634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
    Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
    Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
    Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
    J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS.
    Saiz A; Carreras E; Berenguer J; Yagüe J; Martínez C; Marín P; Rovira M; Pujol T; Arbizu T; Graus F
    Neurology; 2001 Apr; 56(8):1084-9. PubMed ID: 11320183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis.
    Mariottini A; Stack EH; Nair G; Nozzoli C; Wu T; Marchi L; Boncompagni R; Repice AM; Fainardi E; Pasquale FD; Carlesi E; Saccardi R; Jacobson S; Massacesi L
    Mult Scler Relat Disord; 2024 Aug; 88():105745. PubMed ID: 38996712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.
    Muraro PA; Pasquini M; Atkins HL; Bowen JD; Farge D; Fassas A; Freedman MS; Georges GE; Gualandi F; Hamerschlak N; Havrdova E; Kimiskidis VK; Kozak T; Mancardi GL; Massacesi L; Moraes DA; Nash RA; Pavletic S; Ouyang J; Rovira M; Saiz A; Simoes B; Trnený M; Zhu L; Badoglio M; Zhong X; Sormani MP; Saccardi R;
    JAMA Neurol; 2017 Apr; 74(4):459-469. PubMed ID: 28241268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient.
    Obradović D; Tukić L; Radovinović-Tasić S; Petrović B; Elez M; Ostojić G; Balint B
    Vojnosanit Pregl; 2016 May; 73(5):504-8. PubMed ID: 27430119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis.
    Kalincik T; Sharmin S; Roos I; Massey J; Sutton I; Withers B; Freedman MS; Atkins H; Krasulova E; Kubala Havrdova E; Trneny M; Kozak T; Burman J; Macdonell R; Torkildsen Ø; Bø L; Lehmann AK; Sharrack B; Snowden J
    J Neurol Neurosurg Psychiatry; 2024 Jul; 95(8):775-783. PubMed ID: 38538060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial.
    Mancardi GL; Sormani MP; Gualandi F; Saiz A; Carreras E; Merelli E; Donelli A; Lugaresi A; Di Bartolomeo P; Rottoli MR; Rambaldi A; Amato MP; Massacesi L; Di Gioia M; Vuolo L; Currò D; Roccatagliata L; Filippi M; Aguglia U; Iacopino P; Farge D; Saccardi R; ;
    Neurology; 2015 Mar; 84(10):981-8. PubMed ID: 25672923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis.
    Boffa G; Signori A; Massacesi L; Mariottini A; Sbragia E; Cottone S; Amato MP; Gasperini C; Moiola L; Meletti S; Repice AM; Brescia Morra V; Salemi G; Patti F; Filippi M; De Luca G; Lus G; Zaffaroni M; Sola P; Conte A; Nistri R; Aguglia U; Granella F; Galgani S; Caniatti LM; Lugaresi A; Romano S; Iaffaldano P; Cocco E; Saccardi R; Angelucci E; Trojano M; Mancardi GL; Sormani MP; Inglese M;
    Neurology; 2023 Mar; 100(11):e1109-e1122. PubMed ID: 36543569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
    Kalincik T; Sharmin S; Roos I; Freedman MS; Atkins H; Burman J; Massey J; Sutton I; Withers B; Macdonell R; Grigg A; Torkildsen Ø; Bo L; Lehmann AK; Havrdova EK; Krasulova E; Trnený M; Kozak T; van der Walt A; Butzkueven H; McCombe P; Skibina O; Lechner-Scott J; Willekens B; Cartechini E; Ozakbas S; Alroughani R; Kuhle J; Patti F; Duquette P; Lugaresi A; Khoury SJ; Slee M; Turkoglu R; Hodgkinson S; John N; Maimone D; Sa MJ; van Pesch V; Gerlach O; Laureys G; Van Hijfte L; Karabudak R; Spitaleri D; Csepany T; Gouider R; Castillo-Triviño T; Taylor B; Sharrack B; Snowden JA; ; ; Mrabet S; Garber J; Sanchez-Menoyo JL; Aguera-Morales E; Blanco Y; Al-Asmi A; Weinstock-Guttman B; Fragoso Y; de Gans K; Kermode A;
    JAMA Neurol; 2023 Jul; 80(7):702-713. PubMed ID: 37437240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis.
    Mariottini A; Filippini S; Innocenti C; Forci B; Mechi C; Barilaro A; Fani A; Carlucci G; Saccardi R; Massacesi L; Repice AM
    Mult Scler; 2021 Jan; 27(1):61-70. PubMed ID: 32008439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.
    Boffa G; Lapucci C; Sbragia E; Varaldo R; Raiola AM; Currò D; Roccatagliata L; Capello E; Laroni A; Mikulska M; Gualandi F; Uccelli A; Angelucci E; Mancardi GL; Inglese M
    Eur J Neurol; 2020 Oct; 27(10):2047-2055. PubMed ID: 32418281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
    Burt RK; Loh Y; Cohen B; Stefoski D; Balabanov R; Katsamakis G; Oyama Y; Russell EJ; Stern J; Muraro P; Rose J; Testori A; Bucha J; Jovanovic B; Milanetti F; Storek J; Voltarelli JC; Burns WH
    Lancet Neurol; 2009 Mar; 8(3):244-53. PubMed ID: 19186105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis.
    Mariottini A; Bulgarini G; Forci B; Innocenti C; Mealli F; Mattei A; Ceccarelli C; Repice AM; Barilaro A; Mechi C; Saccardi R; Massacesi L
    Eur J Neurol; 2022 Jun; 29(6):1708-1718. PubMed ID: 35146841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study.
    Curro' D; Vuolo L; Gualandi F; Bacigalupo A; Roccatagliata L; Capello E; Uccelli A; Saccardi R; Sormani MP; Mancardi G
    Mult Scler; 2015 Oct; 21(11):1423-30. PubMed ID: 25583838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous stem cell transplant in adult multiple sclerosis patients: A study from North India.
    Dayama A; Bhargava R; Kurmi SR; Jain S; Dua V
    Neurol India; 2020; 68(2):454-457. PubMed ID: 32415023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up more than 10 years after HSCT: a monocentric experience.
    Frau J; Carai M; Coghe G; Fenu G; Lorefice L; La Nasa G; Mamusa E; Vacca A; Marrosu MG; Cocco E
    J Neurol; 2018 Feb; 265(2):410-416. PubMed ID: 29270686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of autografting persons with multiple sclerosis are better in those not exposed to prior disease-modifying therapies.
    Sánchez-Bonilla D; Robles-Nasta M; Gallardo-Pérez MM; Hernández-Flores EJ; Montes-Robles M; Pastelín-Martínez ML; Garcés-Eisele SJ; Olivares-Gazca JC; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
    Mult Scler Relat Disord; 2023 Jul; 75():104744. PubMed ID: 37178580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: Sustained improvement in cognition and quality of life.
    Braun B; Fischbach F; Richter J; Pfeffer LK; Fay H; Reinhardt S; Friese MA; Stellmann JP; Kröger NM; Heesen C; Häußler V
    Mult Scler Relat Disord; 2024 Feb; 82():105414. PubMed ID: 38176284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.